Evicenter
Imbruvica (ibrutinib) in Chronic lymphocytic leukemia and small lymphocytic lymphoma
Manufacturer
Pharmacyclics LLC; Janssen Biotech, Inc.
Prescribing information
Imbruvica (opens in a new tab)
Questions
58
Last updated

All questions

Clinical trials: Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma

20 questions · 15 sources

Subgroup results

Does Imbruvica keep working after a dose reduction (RESONATE-2 post hoc analysis)?

Applies to Adults with previously untreated (first-line) CLL/SLL

How did high-risk CLL patients do on Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: The study design paragraph of the same page lists progression-free survival in the high-risk population as a secondary endpoint.

How effective is Imbruvica for previously treated CLL with 17p deletion (RESONATE)?

Applies to Adults with previously treated CLL/SLL with 17p deletion

Study results

How much does Imbruvica delay CLL progression vs chlorambucil (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Do patients live longer on Imbruvica than chlorambucil (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

What was the response rate with Imbruvica vs chlorambucil (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

How much does Imbruvica plus rituximab delay progression vs FCR (E1912)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: FCR is fludarabine, cyclophosphamide, and rituximab.

What were the overall survival results for Imbruvica plus rituximab vs FCR (E1912)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: FCR is fludarabine, cyclophosphamide, and rituximab.

How much does Imbruvica plus obinutuzumab delay progression vs chlorambucil-obinutuzumab (iLLUMINATE)?

Applies to Adults with previously untreated (first-line) CLL/SLL

What was the response rate with Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Imbruvica vs bendamustine-rituximab: did survival differ in ALLIANCE A041202?

Applies to Adults with previously untreated (first-line) CLL/SLL

Imbruvica vs venetoclax plus obinutuzumab: how did progression-free survival compare (CLL17)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: CLL17 is an investigator-initiated trial that the CLL17 page of the Imbruvica HCP site cites (Al-Sawaf et al., N Engl J Med 2025). These passages report the Imbruvica and venetoclax plus obinutuzumab arms. 1.608 is the prespecified noninferiority margin for the hazard ratio; the page does not state the observed hazard ratio.

How effective is Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

Does Imbruvica improve survival vs ofatumumab in relapsed CLL (RESONATE)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

What was the response rate with Imbruvica vs ofatumumab (RESONATE)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

Does adding Imbruvica to bendamustine-rituximab delay progression (HELIOS)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

What was the response rate with Imbruvica plus bendamustine-rituximab (HELIOS)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

What was the response rate with Imbruvica alone in Study 1102 (previously treated CLL)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

Long-term data

What are the up to 10-year follow-up results of Imbruvica in RESONATE-2?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: The 10-year results are from the final RESONATE-2 analysis that the page cites as data on file and an unpublished abstract.

Clinical trials

Who was enrolled in the Imbruvica RESONATE-2 trial?

Applies to Adults with previously untreated (first-line) CLL/SLL